A Phase 1 interventional study of Ritlecitinib in Healthy Volunteers, Adult and Pharmacokinetics, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare if two forms of study medicine, Ritlecitinib, get processed differently in healthy adults.
This study is seeking participants who are:
The study will take up to 2.5 months, including the screening period. There will be 5 periods in total for this study. Participants will have to stay at the study clinic for at least 11 days. Participants will take Riltecitinib either as sprinkled in Soft Food or as Intact Blend-In Capsule. On day 1 of each period, participants will take Riltecitinib and have blood samples taken both before and afterwards. Participants will also answer questions for taste assessment purpose. A follow-up phone call will be made at 28 to 35 days after the last study period.
Ritlecitinib is a covalent and irreversible inhibitor of JAK3 with high selectivity over the other JAK isoforms (JAK1, JAK2, and TYK2). Ritlecitinib also inhibits irreversibly the tyrosine kinase expressed in TEC family kinases with selectivity over the broader human kinome. Treatment with ritlecitinib is expected to inhibit the inflammatory pathways mediated by IL 7, IL 15 and IL 21, all implicated in UC, CD, AA, RA, and vitiligo. Moreover, due to lack of activity against the other JAK isoforms, ritlecitinib is expected to spare immunoregulatory cytokines such as IL 10, IL 27 and IL 35, which are critical to the maintenance of immunosuppressive functions and immune homeostasis.
The objective of this study is to estimate the impact of administration methods on the bioavailability of the pediatric ritlecitinib intact BiC formulation. The study will be conducted as a Phase 1, open-label, single dose, randomized, 4-crossover periods and 1-fixed period design in a single cohort of approximately 12 healthy male or female participants at a single center. Participants will be randomized into 1 of 4 sequences of treatment. Blood samples will be collected for PK analysis. A taste assessment will be also conducted.
Participants will participate in the study for up to approximately 2.5 months, with the inclusion of the screening and follow-up period. On Day 1 of each period, participants will receive a single dose of IP. Administration of IP will be via dosing using intact BiCs with water or by emptying the capsule contents on soft food as per dosing instructions.
Participants will be confined in the CRU for a total of at least 11 days and discharged at the discretion of the investigator. A follow-up phone call will be made at least 28 calendar days and up to 35 calendar days after the last administration of the study intervention to capture any potential AE and confirm appropriate contraceptive usage.
Tolerability and safety will be assessed for all treatments by monitoring AEs.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ritlecitinib 1 x 30 milligram (mg) intact blend-in-capsule (BiC) in fasted state
Drug: Ritlecitinib
contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on strawberry jam in fasted state
Drug: Ritlecitinib
contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on yoghurt in fasted state
Drug: Ritlecitinib
contents of ritlecitinib 1 x 30 mg intact BiC sprinkled on applesauce in fasted state
Drug: Ritlecitinib
ritlecitinib 1 x 30 mg intact BiC given with high fat meal
Drug: Ritlecitinib
ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E) ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)
Also known as: PF-06651600
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib
AUCinf was defined as area under the plasma-concentration time profile from time zero extrapolated to infinite time. AUCinf for ritlecitinib was calculated by AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose on Day 1 of each period. Each treatment period lasted 24 hours. Dosing of each period was separated by at least a 48-hour washout interval.
Maximum Observed Concentration (Cmax) of Ritlecitinib
Cmax was defined as maximum observed plasma concentration. Cmax for ritlecitinib was observed directly from data.
Time frame: 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12 and 24 hours post-dose on Day 1 of each period. Each treatment period lasted 24 hours. Dosing of each period was separated by at least a 48-hour washout interval.
Number of Participants With All-Causality and Treatment-Related Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events were events between first dose of study treatment and up to approximately 35 days that were absent before treatment or that worsened relative to pretreatment state.
Time frame: From the first dose of study treatment up to 28-35 days after last dose of study treatment (ie, up to 45 days)
Number of Participants With Laboratory Abnormalities
Hematology included hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet and white blood cell count, total neutrophils, eosinophils, etc. Chemistry included blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, etc. Urinalysis included pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin and microscopy. Laboratory abnormalities were judged by the investigator. Laboratory abnormalities reported for at least 1 participant in the whole study are presented here.
Time frame: From the first dose of study treatment up to 28-35 days after last dose of study treatment (ie, up to 45 days)
| Milestone | Sequence 1: Treatment A-> B-> C-> D-> E | Sequence 2: Treatment B-> D-> A-> C-> E | Sequence 3: Treatment C-> A-> D-> B-> E | Sequence 4: Treatment D-> C-> B-> A-> E |
|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: Treatment A-> B-> C-> D-> E | Sequence 2: Treatment B-> D-> A-> C-> E | Sequence 3: Treatment C-> A-> D-> B-> E | Sequence 4: Treatment D-> C-> B-> A-> E |
|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: Treatment A-> B-> C-> D-> E | Sequence 2: Treatment B-> D-> A-> C-> E | Sequence 3: Treatment C-> A-> D-> B-> E | Sequence 4: Treatment D-> C-> B-> A-> E |
|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: Treatment A-> B-> C-> D-> E | Sequence 2: Treatment B-> D-> A-> C-> E | Sequence 3: Treatment C-> A-> D-> B-> E | Sequence 4: Treatment D-> C-> B-> A-> E |
|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: Treatment A-> B-> C-> D-> E | Sequence 2: Treatment B-> D-> A-> C-> E | Sequence 3: Treatment C-> A-> D-> B-> E | Sequence 4: Treatment D-> C-> B-> A-> E |
|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 |
| Completed | 3 | 2 | 3 | 2 |
| Not completed | 0 | 1 | 0 | 1 |
| Withdrew: Not completing the meal | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
AUCinf was defined as area under the plasma-concentration time profile from time zero extrapolated to infinite time. AUCinf for ritlecitinib was calculated by AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.
| nanogram*hour per milliliter (ng*hr/mL) | Ritlecitinib 30 mg Capsule (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted) | Ritlecitinib 30 mg Capsule Given With High Fat Meal |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib | 389.1 ± 32 | 398.3 ± 31 | 378.0 ± 27 | 387.8 ± 27 | 387.0 ± 23 |
Cmax was defined as maximum observed plasma concentration. Cmax for ritlecitinib was observed directly from data.
| ng/mL | Ritlecitinib 30 mg Capsule (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted) | Ritlecitinib 30 mg Capsule Given With High Fat Meal |
|---|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) of Ritlecitinib | 244.3 ± 35 | 236.1 ± 28 | 206.6 ± 24 | 229.4 ± 25 | 108.0 ± 28 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent events were events between first dose of study treatment and up to approximately 35 days that were absent before treatment or that worsened relative to pretreatment state.
| Participants | Ritlecitinib 30 mg Capsule (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted) | Ritlecitinib 30 mg Capsule Given With High Fat Meal |
|---|---|---|---|---|---|
| Number of participants with all-causality TEAEs | 5 | 2 | 4 | 4 | 2 |
| Number of participants with all-causality SAEs | 0 | 0 | 0 | 0 | 0 |
| Number of participants with treatment-related TEAEs | 2 | 0 | 1 | 0 | 1 |
| Number of participants with treatment-related SAEs | 0 | 0 | 0 | 0 | 0 |
Hematology included hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet and white blood cell count, total neutrophils, eosinophils, etc. Chemistry included blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, etc. Urinalysis included pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin and microscopy. Laboratory abnormalities were judged by the investigator. Laboratory abnormalities reported for at least 1 participant in the whole study are presented here.
| Participants | Ritlecitinib 30 mg Capsule (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted) | Ritlecitinib 30 mg Capsule Given With High Fat Meal |
|---|---|---|---|---|---|
| Number of Participants With Laboratory Abnormalities | 0 | 0 | 0 | 0 | 0 |
Collected over From the first dose of study treatment up to 28-35 days after last dose of study treatment (ie, up to 45 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ritlecitinib 30 mg Capsule (Fasted) | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted) | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted) | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted) | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Ritlecitinib 30 mg Capsule Given With High Fat Meal | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Event | Ritlecitinib 30 mg Capsule (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Strawberry Jam (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Yoghurt (Fasted) | Ritlecitinib 30 mg Capsule Mixed With Applesauce (Fasted) | Ritlecitinib 30 mg Capsule Given With High Fat Meal |
|---|---|---|---|---|---|
| HaematomaVascular disorders | 1/12 | 1/12 | 2/12 | 4/12 | 0/10 |
| AcneSkin and subcutaneous tissue disorders | 0/12 | 0/12 | 0/12 | 0/12 | 2/10 |
| ToothacheGastrointestinal disorders | 0/12 | 0/12 | 0/12 | 0/12 | 1/10 |
| Dry eyeEye disorders | 0/12 | 0/12 | 1/12 | 0/12 | 0/10 |
| Abdominal discomfortGastrointestinal disorders | 1/12 | 0/12 | 0/12 | 0/12 | 0/10 |
| Abdominal painGastrointestinal disorders | 0/12 | 0/12 | 1/12 | 0/12 | 0/10 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/12 | 1/12 | 0/12 | 0/10 |
| Dry mouthGastrointestinal disorders | 1/12 | 0/12 | 0/12 | 0/12 | 0/10 |
| Lip dryGastrointestinal disorders | 1/12 | 0/12 | 0/12 | 0/12 | 0/10 |
| FatigueGeneral disorders | 1/12 | 0/12 | 0/12 | 0/12 | 0/10 |
All participants who were enrolled in the study.
| Age, Continuous(Years) | All Participants |
|---|---|
| Mean | 40.4 ± 12.99 |
| Age, Customized(Participants) | All Participants |
|---|---|
| 26-35 years | 6 |
| 36-45 years | 3 |
| >45 years | 3 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 4 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | All Participants |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 11 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 8 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from May 2023 to primary completion in Jun 2023, 1 month.
Results were first posted in Oct 2024, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600